MBIO   $0.49  6.12% Market Closed

Mustang Bio Inc
Last Events:

2023-03-29 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: up-crossing the middle level.

2023-03-29 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-29 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-03-29 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-03-29 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: up-crossing the middle level.

2023-03-29 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: entrance to the overbought zone.

2023-03-29 Signal in EMA50 changed from bullish reversal to bearish reversal. 2022-11-21 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-29 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 2.65
ST: 0, Cor:

50-50 Year Forecast
Low with 51% probability: 0.46
Target: 5.00
High with 48% probability: 1.50
Analyst Recommendations:
Number of estimates 5
Target Price Mean 5.00
Mean unverified/preliminary 5.00 / 5.00
Target Price Low / High 4.00 / 7.00
Median / STD DEV 4.00 / 1.41
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell Sell
macd Sell - Sell
stoch Sell Sell -
ma20 Sell - -
ma50 - Sell -
ma100 Sell - -
Candlestick PatternMarch 9, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US62818Q1040
ceo Dr. Manuel Litchman M.D.
Website https://www.mustangbio.com
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.